Trial Profile
A multi-center, open-label clinical pharmacology study for comparative investigation of the pharmacokinetics, tolerability, and safety of three types of brexpiprazole (OPC-34712) once-weekly (QW) formulation administered as single oral doses in patients with schizophrenia
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 06 Sep 2023 Planned number of patients changed from 36 to 50.
- 20 Apr 2018 New trial record